HISTOPATHOLOGY AND MOLECULAR PATHOLOGY

组织病理学和分子病理学

• 批准号: 6300210
• 负责人: PELAYO none CORREA
• 金额: $ 29.8万
• 依托单位: LSU HEALTH SCIENCES CENTER
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-03-10 至 2003-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6300210
• 关键词: DNA damage; Helicobacter; antibacterial agents; antioxidants; biomarker; biopsy; cell cycle; clinical research; gastric mucosa; gastritis; gastrointestinal epithelium; gastrointestinal neoplasms; gene expression; gene rearrangement; histopathology; human subject; immunoperoxidase; metaplasia; molecular oncology; mucins; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; oxidative stress; preneoplastic state; tumor suppressor genes

This project evaluates the endpoints to determine the status and the evolution of the lesions of the gastric mucosa utilizing histopathological, immunochemical and molecular biology techniques. Biopsies taken from 8 specific locations in the gastric mucosa in patients from Colombia and New Orleans will be assigned a global diagnosis based on the most advanced lesion and detailed assessment of the following parameters" polymorphonuclear, and mononuclear leukocytic infiltration, damage to epithelial cells, atrophy, metaplasia, mucins, Lewis antibodies, Ki 67 labelling index, inducible nitric oxide synthase, nitrotyrosine, apoptosis, p53 abnormalities, TPR-MET expression and microsatellite destabilization. The techniques for the utilization of these markers are described in the text and are thoroughly familiar to the investigators. The different interventions described in the other projects, especially anti-Helicobacter pylori therapy and administration of antioxidants are directed to modify the phenotypic events in the precancerous process. The markers chosen are intended to evaluate those changes with state of the art techniques in pre- and post-intervention biopsies. Each marker will be evaluated independently and combinations of them will be designed and tested to develop measures of change of the precancerous process in terms of single and combined scores.

此项目评估终结点以确定状态和 利用组织病理学研究胃粘膜病变的演变， 免疫化学和分子生物学技术。取自8份活组织检查 哥伦比亚和新西兰患者胃粘膜的特定部位 奥尔良将被分配基于最先进的 损害和对以下参数的详细评估“ 中性粒细胞和单核细胞浸润，损害 上皮细胞，萎缩，化生，粘蛋白，Lewis抗体，Ki 67 标记指数、诱导型一氧化氮合酶、硝基酪氨酸、细胞凋亡 P53异常、TPR-MET表达和微卫星失稳。 使用这些标记的技术在 文本，调查人员对此非常熟悉。不同的 其他项目中描述的干预措施，特别是抗幽门螺杆菌 幽门螺杆菌治疗和抗氧化剂的应用旨在改变 癌前病变过程中的表型事件。所选的标记为 旨在用最先进的技术评估这些变化 和介入后的活组织检查。将对每个标记进行评估 它们的独立和组合将被设计和测试以 从单一的角度制定改变癌前过程的措施 和综合分数。